Previously, chloramphenicol and tetracycline were used to treat scrub typhus; currently, doxycycline is the most frequently used treatment [7] . Doxycycline may be recommended for 3 days if the case is not severe but it is generally recommended for 5-7 days because recurrence may occur. Usually, the fever clears within 48 hours after treatment. However, persistent fever despite treatment with doxycycline was reported in northern Thailand in the 1990s, indicating that O. tsutsugamushi might be resistant to doxycycline [8] .
In Thailand where cases of doxycycline resistance were reported, a study comparing the efficacy of rifampin and doxycycline found that fever subsided sooner and recurrence did not occur in the group treated with rifampin [9] . However, research has not been conducted to compare the drugs in an area in which doxycycline resistance has not been reported. Accordingly, in the present study, our aim was to investigate the efficacy of rifampin in patients with scrub typhus.
2007 and 2009. Patients aged ≥18 years with body temperature of 37.5°C or higher, eschar or maculopapular rash, and clearance of at least 2 of the following symptoms: headache, fatigue, muscular ache, cough, nausea, and abdominal discomfort. Pregnant women; patients who were unable to take oral medications; patients with allergies to doxycycline or rifampin (self-reported); patients with scrub typhus who were treated with doxycycline, rifampin, and macrolides within 48 hours before admission; severely ill patients (shock patients with blood pressure <90 mm Hg at the time of admission, unconscious patients or those suspected of having meningitis, and patients with respiratory failure requiring a ventilator or with acute renal failure); patients with gastrointestinal bleeding; and patients requiring a differential diagnosis of other similar diseases (eg, leptospirosis or hemorrhagic fever with renal syndrome) were excluded from the study. Patients or guardians signed a written consent form before the study was conducted. The Chosun University Hospital Institutional Review Board approved the study.
The diagnosis of scrub typhus was confirmed if an indirect immunofluorescent antibody (IFA) assay immunoglobulin (Ig) M titer against O. tsutsugamushi (Gilliam, Karp, Kato and Boryoung) increased to 1:80 or more, if an IFA titer (IgM or IgG) against O. tsutsugamushi increased 4 times or more [10] , or if the result of a nested polymerase chain reaction (PCR) targeting the O. tsutsugamushi-specific 56-kDa protein gene, using a blood buffy coat or an eschar to amplify a 483-bp fragment, was positive [11] . Vital signs were recorded on a daily basis with a 4-hour interval until defervescence and then with an 8-hour interval while the patients remained in the hospital. After discharge, the patients were followed up once a week for 4 weeks. To assess for recurrence of symptoms, the patients were examined during outpatient follow-up visits and 1 month after discharge via telephone.
Research Design
Patients who signed a consent form for clinical trial participation were randomly assigned to 1 of 2 groups and were prospectively followed up. Patients whose resident registration number ended with an odd number were given doxycycline 100 mg twice daily for 5 days, and those whose resident registration number ended with an even number were given rifampin 600 mg once daily for 5 days. Drug administration was initiated immediately after a physical exam, blood tests, and other tests such as chest X-ray and, if necessary, computed tomography scan.
Outcome Assessment
The primary outcome in assessing the treatment effect was the time to fever clearance (an axillary temperature measurement, taken every 4 hours). The time to fever clearance was defined as the period from the initial drug administration until the body temperature decreased to 37.3°C or lower and remained below this temperature for at least 48 hours without the use of an antipyretic.
The secondary outcome was categorized as complete cure, failure, or recurrence. Patients were classified as complete cure if their fever was clear within 5 days after drug administration, failure if fever persisted for more than 5 days without obvious reasons, and recurrence if fever or other clinical symptoms recurred within 30 days after the patient was determined to be completely cured [12] .
Patients with toxicities (elevated liver function test and elevated creatinine level) and adverse effects that did not occur before drug administration but manifested within the course of treatment were closely followed up. These patients were examined irrespective of other factors or medications associated with hospitalization or regardless of the natural course of scrub typhus.
Sample Size and the Basis of Sample Size Estimation
According to Blackwelder (ie, research on the equivalence of 2 drugs) [13] , at least 87 patients per group were required. If the cure rate of doxycycline was assumed to be 90%, nonequivalence was defined as a between-group difference of cure rate of 15% or higher, and type I and II errors were set at 0.05 and 0.20, respectively [12] . Considering a dropout rate of 20%, 220 or more patients needed to be recruited so that there would be at least 110 patients per group.
Statistical Analyses
Pearson χ 2 test was used to compare between-group characteristics before drug administration (ie, to examine whether both groups were appropriately assigned), and an independent t test was conducted to compare the times to clear fever, headache, muscle ache, and rash between groups after drug administration. In addition, the Kaplan-Meier survival function was used to compare the time to clear fever, and the log-rank test was performed to compare the cure rate between groups. The analysis of efficacy data was based on the laboratory-confirmed cases of scrub typhus as well as intention-to-treat analysis. Statistical significance was defined as a P value < .05. All data analyses were performed using SPSS, version 17.0.
RESULTS

Demographic and Clinical Characteristics
A total of 421 patients who were suspected to have scrub typhus accompanied by rash and fever were admitted to Chosun University Hospital and 2 regional network hospitals (Jangheung Hospital and Haenam Hospital) between January 2007 and December 2009. Of those, 175 did not meet the selection criteria and were excluded from the study. Of the remaining 246 patients, 43 had a body temperature less than 37.5°C, 32 with scrub typhus were given antibiotics to be effective for scrub typhus at another hospital within 48 hours before admission, 30 were uncertain whether an antibiotic/nonsteroidal antiinflammatory drug was administered before admission, and 25 with shock, unconsciousness, meningitis, acute renal failure, or respiratory failure were classified as severely ill. The remaining 45 patients participated in the study. Overall, 246 patients met the enrollment criteria and were given 1 of 2 antibiotics based on the last digit of their resident registration number. Six of those enrolled were excluded owing to the co-occurrence of other febrile diseases such as hemorrhagic fever with renal syndrome, cellulitis, and lupus. After excluding those 6 patients, 121 of the remaining 240 were treated with doxycycline and 119 were treated with rifampin. Each drug was administered daily for 5 days in both groups, and treatment outcomes were subsequently evaluated. Before treatment was initiated, patients' demographic data such as age and sex, clinical data such as presence and duration of symptoms before admission, and blood test results were reviewed. Results showed that these data were not significantly different between the groups. The demographic data, clinical characteristics, and laboratory data for patients in both groups are listed in Table 1 . The following were the diagnostic criteria for scrub typhus: if the IgM antibody titers against O. tsutsugamushi increased to 1:80 or more, if the IgM or IgG antibody titers increased 4 times or more, or if the result of the PCR test was positive. The proportions of patients with a confirmed diagnosis of scrub typhus were similar between the groups: 83 of the 121 patients in the doxycycline group (87.4% of 95 patients with a confirmed diagnosis) and 75 of the 119 patients in the rifampin group (86% of 88 patients with a confirmed diagnosis). The data for patients with confirmed and unconfirmed diagnosis were also included.
Comparison of Treatment Effect Between Groups
The primary treatment outcome was based on the laboratory-confirmed cases of scrub typhus. The median time (interquartile range) to fever clearance was 22.0 (12.0-24.0) hours in the doxycycline group and 18.0 (12.0-24.0) hours in the rifampin group. Thus, the latter group' s time for fever clearance was shorter, but the difference was not statistically significant (P = .241; Table 2 ). A log-rank test using a Kaplan-Meier curve was performed to compare the time to fever clearance between groups; the results showed no significant difference ( Figure 1) . A rapid response to treatment characterized There were no significant differences in the baseline characteristics of patients with confirmed scrub typhus except for the white blood cell count and ESR between the 2 groups (P > .05). The values are expressed as median with interquartile ranges. Abbreviations: Alk-p, alkaline phosphatase; ALT, alanine aminotransferases; AST, aspartate aminotransferase; CPK, creatine phosphokinase; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; LDH, lactate dehydrogenase.
by fever clearance within 48 hours or absence of fever at admission was observed in 89.0% of the patients in the doxycycline group and 93.2% of the patients in the rifampin group; however, the difference between the groups was not statistically significant (P = .414). Moreover, the times to clear headache, muscle ache, and rash were not significantly different between the groups (Table 2 ). An intention-to-treat analysis was performed and showed no significant difference in the time to clear fever, headache, muscle ache, or rash.
Regarding the proportion of complete cures, all patients in both groups were completely cured except for 1 in the doxycycline group (Table 3) who was classified as failure based on the intention-to-treat analysis. The patient was suspected of having scrub typhus as he presented the typical symptoms of the disease, such as fever, headache, and rash, and had a history of performing outdoor activities. The results of the PCR and IFA tests to detect O. tsutsugamushi were negative. Therefore, patients with confirmed cases of scrub typhus were excluded from the analysis.
Comparison of Side Effects
In both confirmed patient groups, drug-related fatalities or other severe adverse effects were not present. The proportion of patients in the doxycycline group who experienced side effects was 15.6% (13/83) and proportion in the rifampin group was 16% (12/75). In the former group, 2 had diarrhea. In the latter group, 1 experienced nausea and vomiting, 1 had stomach ache, and 1 had diarrhea. Drug-induced hepatic dysfunction is characterized by a 2-fold increase in the blood aspartate aminotransferase and alanine aminotransferase levels (measures of hepatic dysfunction) before the medication was administered. Approximately 6.0% of patients (5 of 83) in the doxycycline group and 8.0% (6 of 75) in the rifampin group had drug-induced hepatic dysfunction. Three patients in the doxycycline group and 1 in the rifampin group had a rash, and 4 patients in each of the doxycycline and rifampin groups experienced esophageal candidiasis [4] . Otherwise, the side effects were relatively mild in both groups. There were no significant differences in the side effects reported by both groups.
DISCUSSION
Chloramphenicol and tetracycline have been used to treat scrub typhus, but the use of chloramphenicol has been discontinued in Korea because it can cause adverse effects on the fetus, including aplastic anemia, myelosuppression, and gray baby syndrome. Additionally, doxycycline resistance in some strains was reported recently. Hence, the development of new treatment options is urgently needed [10, 14, 15] . Macrolides such as azithromycin and telithromycin, which can be used in children and pregnant women, have been reported as effective, and quinolones such as ciprofloxacin have also been found as effective alternatives [7, [16] [17] [18] . However, according to a metaanalysis, the median time to fever clearance was longer in patients treated with azithromycin than in those treated with chloramphenicol, and adverse effects were 2.95 times more common [19] . In addition, the clearance times for fever, headache, and rash were shorter in patients treated with doxycycline than in patients treated with chloramphenicol. Thus, the development of new medications that are more effective than azithromycin or chloramphenicol is needed. There were no significant differences in the time elapsed when symptoms disappeared between the 2 groups (P > .05). Values are expressed as median with interquartile ranges.
Rifampin is an inhibitor of bacterial DNA-dependent RNA polymerase and is highly efficacious as a treatment for intracellular pathogens because it has a high level of intracellular penetration. Furthermore, it is a broad-spectrum agent with the spectrum of in vitro activity effective not only against Staphylococcus, Streptococcus spp., and Listeria monocytogenes but also against Chlamydia spp., Legionella spp., and Brucella spp.
Some strains of O. tsutsugamushi identified in northern Thailand were found to be resistant to the existing standard antibiotic therapy, specifically doxycycline. Following a mouse study in which rifampin showed superior antimicrobial activity over doxycycline against these strains, a randomized trial including 89 patients with scrub typhus (40 in the doxycycline group, 38 in the rifampin group, and 11 treated with combination therapy) found superior clinical efficacy of rifampin monotherapy over the other treatment approaches [20] . However, no study has been conducted to compare doxycycline and rifampin in an area where doxycycline resistance has not yet been reported.
Central nervous system (CNS) invasion is relatively common in O. tsutsugamushi infections as DNA was confirmed in the cerebrospinal fluid (CSF) [21] and meningoencephalitis can occur, even while patients are treated with doxycycline [22] . Rifampin could be of particular benefit in patients with CNS involvement due to the adequate rifampin concentration in the CSF [23] . However, patients should be closely monitored because rifampin can cause hepatotoxicity as well as hematologic adverse effects and cerebral infarction, and hemorrhage has been reported to occur following rifampin administration [24] .
In this study, rifampin was shown to be comparable with doxycycline in terms of efficacy and safety. Tuberculosis is prevalent in most areas of Southeast Asia and Korea where scrub typhus frequently occurs. Therefore, rifampin should be used with caution because drug abuse increases the possibility of occurrence of drug-resistant Mycobacterium tuberculosis.
This study has some limitations. We did not measure the patients' body temperature after discharge for relapse assessment. We only checked for the presence of any febrile sensation or symptom aggravation. However, none of the patients with scrub typhus complained of fever after completing the 5-day doxycycline treatment. Patients complained of general weakness and mild headache, but these symptoms improved over time. However, it is difficult to diagnose and differentiate scrub typhus from other acute febrile diseases such as dengue fever, leptospirosis, malaria, and other viral hemorrhagic fevers because the symptoms are very similar; however, but the large number of confirmed cases in this study was clinically significant.
In conclusion, in an area where resistance to doxycycline has not been reported, treatment efficacy and safety were observed in patient groups that received 600 mg of rifampin or 200 mg of doxycycline for 5 days to treat uncomplicated scrub typhus. Accordingly, rifampin may be considered as a therapeutic alternative treatment in patients with scrub typhus in situations where doxycycline is contraindicated or where a doxycycline-resistant strain has been reported. 
